An Overview on Mucormycosis in Covid-19 Patients
Article Sidebar
-
Mucormycosis, Covid-19, CT scan, diabetic patients
Abstract
The devastating COVID-19 pandemic has brought the world into a new era of Public Health problems. After the first and second waves of the COVID-19 infection, the world saw a unique pattern of post-covid complications, which were even more dangerous than the alone COVID- 19 infection. The second wave brought with it the deadly Mucormycosis, which was commonly known as Black Fungus. The extreme use of steroids in managing covid infection and the covid patients with multiple comorbidities were the most affected population with the black fungus disease. The fungal strain Rhizopus oryzae was a dominantly reported etiologic pathogen for the occurrence of fungal infection called Mucormycosis in COVID patients. The baseline signs & symptoms known are characterized by Acute sinusitis, Prolonged fever, Headache, Nasal and Sinus congestion, Purulent nasal discharge, Black lesion on the upper palate & on nasal bridge, Unilateral facial edema, Numbness, Orbital swelling, Periorbital cellulitis, Blurring of vision, Conjunctival suffusion, Central retinal artery occlusion, Dry ulcers, Abscesses, Proptosis, Palatal or Palpebral fistula developing into necrosis, hyphal angioinvasion resulting into thrombosis and tissue infarction, Soft tissue necrosis and marked chemosis. The traditional treatment modes used were antifungal therapy, surgical debridement, supportive therapy and surgical/prosthetic rehabilitation the recent management of mucormycosis as released by ECMM under the ―One World One Guideline initiative in 2019 provides a detailed algorithm for the successful treatment of mucormycosis. In this article, we have compiled complete information about post-COVID Mucormycosis.
Full text article
References
Y R Guo, Q D Cao, Z S Hong, Y Y Tan, S D Chen, and H-J Jin. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res, 7(1):11–11, 2020.
J Kearney. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: A Review. Medicine & Pharmacology, 2020.
A Mukherjee, M Ahmad, D Frenia, and Coronavirus Disease. Coronavirus Disease 2019 (COVID-19) Patient with Multifocal Pneumonia Treated with Hydroxychloroquine. Cureus, 2019.
F Danion, A Coste, Le Hyaric, C Melenotte, C Lamoth, and F Calandra. What Is New in Pulmonary Mucormycosis? Journal of Fungi, 9(3):307–307, 2023.
R Laturiya, S Badal, A Doiphode, G Nagargoje, S Bhale, and M Sonare. Rising Incidence Of Mucormycosis During Covid 19: A Review. 2:5–5, 2020.
H Prakash, A K Ghosh, S M Rudramurthy, P Singh, I Xess, and J Savio. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol, 57(4):395–402, 2019.
G Song. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. 8, 2020.
A S Ibrahim, B Spellberg, T J Walsh, and D P Kontoyiannis. Pathogenesis of Mucormycosis. Clin Infect Dis, 54(suppl_1):16–22, 2012.
O A Cornely, A Alastruey-Izquierdo, D Arenz, Sca Chen, E Dannaoui, and B Hochhegger. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis, 19(12):405–426, 2019.
M B Gillespie, O Malley, and B W. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am, 33(2):323–357, 2000.
E Roilides, T Zaoutis, A Katragkou, D Benjamin, and T Walsh. Zygomycosis in Neonates: An Uncommon but Life-threatening Infection. Am J Perinatol, 26(08):565–73, 2009.
K S Chugh, V Sakhuja, K L Gupta, V Jha, A Chakravarty, and N Malik. Renal Mucormycosis: Computerized Tomographic Findings and Their Diagnostic Significance. Am J Kidney Dis, 22(3):393–400, 1993.
L I Jianhong, H U Xianliang, and J Xuewu. Isolated Renal Mucormycosis in Children. J Urol, 171(1):387–395, 2004.
S Sarkar, T Gokhale, S Choudhury, and A Deb. COVID-19 and orbital mucormycosis. Indian J Ophthalmol, 69(4):1002–1002.
B Spellberg, J Edwards, and A Ibrahim. Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. Clin Microbiol Rev, 18(3):556–69, 2005.
T M John, C N Jacob, and D P Kontoyiannis. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi, 7:298–298, 2021.
J P Gangneux, M E Bougnoux, E Dannaoui, M Cornet, and J R Zahar. Invasive fungal diseases during COVID-19: We should be prepared. J Mycol Médicale, 30(2):100971–100971, 2020.
S S Dadwal and D P Kontoyiannis. Recent advances in the molecular diagnosis of mucormycosis. Expert Rev Mol Diagn, 18:845–54, 2018.
X Yang, Y Yu, J Xu, H Shu, J Xia, and H Liu. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 8(5):475–81, 2020.
N Chen, M Zhou, X Dong, J Qu, F Gong, and Y Han. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395:507–520, 2020.
D Pasero, S Sanna, C Liperi, D Piredda, G P Branca, and L Casadio. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection, 2020.
M S Lionakis and D P Kontoyiannis. Glucocorticoids and invasive fungal infections. The Lancet, 362:1828–1866, 2003.
Raghavendra Rao et al. Post-COVID pulmonary mucormycosis - A case report. IP Indian J Immunol Respir Med, 6(1):62–68, 2021.
N A Osman, M M Anwar, B Singh, G K Gupta, and A M Rabie. A peek behind the curtain in the diagnosis and management of COVID 19 Associated Mucormycosis (CAM). The Journal of the Egyptian Public Health Association, 98, 2023.
H Prakash and A Chakrabarti. Global Epidemiology of Mucormycosis. J Fungi, 5(1):26–26, 2019.
B Spellberg, D P Kontoyiannis, D Fredricks, M I Morris, J R Perfect, and P V Chin-Hong. Risk factors for mortality in patients with mucormycosis. Med Mycol, 50(6):611–619, 2012.
P L White, R Dhillon, Cordey A Hughes, H Faggian, and F Soni. A National Strategy to Diagnose Coronavirus Disease 2019 - Associated Invasive Fungal Disease in the Intensive Care Unit. Clin Infect Dis, 2020.
X Chen, B Zhao, Y Qu, Y Chen, J Xiong, and Y Feng. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease. Clin, 71(8):1937–1979, 2019.
A Arastehfar, A Carvalho, F L Van De Veerdonk, J D Jenks, P Koehler, and R Krause. COVID-19 Associated Pulmonary Aspergillosis (CAPA)- From Immunology to Treatment. J Fungi, 6(2):91–91, 2020.
S Mehta and A Pandey. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus, 2020.
M Sen, S Lahane, T Lahane, R Parekh, and S Honavar. Mucor in a Viral Land: A Tale of Two Pathogens. Indian J Ophthalmol, 69(2):244–244.
M Saldanha, R Reddy, and M J Vincent. Title of the Article: Paranasal Mucormycosis in COVID- 19 Patient. Indian J Otolaryngol Head Neck Surg, 2021.
K Garlapati, S Chavva, R M Vaddeswarupu, and J Surampudi. Fulminant Mucormycosis Involving Paranasal Sinuses: A Rare Case Report. Case Rep Dent, 2014:1–4, 2014.
B J Ferguson. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am, 33(2):349–65, 2000.
A S Ibrahim, B Spellberg, and J Edwards. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis, 21:620–625, 2008.
W M Artis, J A Fountain, H K Delcher, and H E Jones. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes, 31:1109–1123, 1982.
H Y Sun and N Singh. Mucormycosis: its contemporary face and management strategies.
Lancet Infect Dis, 11(4):301–312, 2011.
T M Rawson, Lsp Moore, N Zhu, N Ranganathan, K Skolimowska, and M Gilchrist. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis, 530, 2020.
N Khan, C G Gutierrez, D V Martinez, and K C Proud. A case report of COVID-19 associated pulmonary mucormycosis. Arch Clin Cases, 07:46–51, 2020.
Authors
Copyright (c) 2023 International Journal of Research in Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Article Details
